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Abstract
Background
The recent genome-wide association studies (GWAS) in inflammatory bowel disease (IBD)
suggest significant genetic overlap with complex mycobacterial diseases like tuberculosis or
leprosy. TLR variants have previously been linked to susceptibility for mycobacterial dis-
eases. Here we investigated the contribution to IBD risk of two TLR2 polymorphisms, the
low-prevalence variant Arg753Gln and the GTn microsatellite repeat polymorphism in intron
2. We studied association with disease, possible correlations with phenotype and gene-
gene interactions.
Methodology/Principal findings
We conducted a large study in 843 patients with Crohn’s disease, 426 patients with ulcera-
tive colitis and 805 healthy, unrelated controls, all of European origin. Overall, the frequency
for carriers of shorter GTn repeats in intron 2 of the TLR2 gene, which have previously been
associated with low TLR2 expression and high IL-10 production, was slightly elevated in
Crohn’s disease and ulcerative colitis compared to healthy controls (16.0% resp. 16.7% vs.
12.8%). The highest frequency of short GTn carriers was noted among IBD patients on anti
TNF-alpha therapy. However, none of these differences was significant in the multivariate
analysis. The Arg753Gln polymorphism showed no association with any clinical subtype of
IBD, including extensive colitis, for which such an association was previously described. We
found no association with specific phenotypic disease subgroups. Also, epistasis analysis
revealed no significant interactions between the two TLR2 variants and confirmed IBD sus-
ceptibility genes.
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Conclusions
The two functional relevant polymorphisms in TLR2, the GTn microsatellite repeat polymor-
phism in intron 2 and the Arg753Gln variant do not seem to play a role in the susceptibility to
Crohn’s disease or ulcerative colitis.
Introduction
Among complex diseases some of the most notable progress has been made in the genetic
characterisation of the inflammatory bowel diseases (IBD) Crohn’s disease (CD) and ulcerative
colitis (UC). Large-scale genome-wide association studies (GWAS) and extensive meta-analy-
ses facilitated by international collaborative research groups led to the identification of 200
IBD-associated loci, of which 163 are associated with both diseases, 37 are CD specific and 27
are UC specific [1, 2]. Besides shared loci for IBD and other immune-mediated disorders such
as psoriasis and ankylosing spondylitis, one of the key findings of the latest meta-analyses of
the GWAS and ImmunoChip data is a considerable overlap between susceptibility for IBD
and mycobacterial infection: six of the eight known autosomal genes linked to Mendelian sus-
ceptibility to mycobacterial disease are located within IBD loci; as regards complex mycobacte-
rial disease, seven CD susceptibility genes overlap with leprosy susceptibility genes [1].
Toll-like receptors are transmembrane proteins usually expressed by antigen presenting
cells; they act as receptors of the innate immune system by recognizing specific pathogen-asso-
ciated molecular patterns with subsequent activation of immune responses. In the digestive
system TLRs can recognize invading microbes in the intestinal barrier and activate immune
responses. However, an over-activation of these receptors may lead to chronic intestinal
inflammation. Because of the ability of TLRs to recognise particular molecular patterns of
diverse microorganisms, their contribution to disease susceptibility has been studied for vari-
ous mycobacterial diseases as well as for IBD. Several observations report an association of
TLR variants with mycobacterial disease [3]. Regarding IBD, variants in TLR4 have consis-
tently been associated with CD and UC [4] and interactions between a TLR9 variant and
replicated CD susceptibility loci seem to modulate disease susceptibility [5]. Functional poly-
morphisms in TLR2, which result in impaired response to bacterial lipoproteins or influence
promotor activity [6, 7], have also been repeatedly associated with susceptibility to mycobacte-
rial disease [8] and other infectious conditions [9] as well as common conditions such as atopic
sensitization in the general population [10].
Genetic factors identified by GWAS explain only a modest part of disease variance in IBD
(about 13.6% for CD and 7.5% for UC) [1]. This implies that other factors such as environ-
mental exposure, epigenetics but also genetic factors not captured by GWAS contribute sub-
stantially to disease pathogenesis. Risk loci with a minor allele frequency >5% in the general
population and an odds ratio (OR) >1.2 have presumably all been identified in IBD patients
with European ancestry. Other genetic risk factors such as rare variants, copy number varia-
tions and microsatellite polymorphisms, however, are still expected to be identified. In the
present study we examined in a large European population the contribution to susceptibility
for IBD of two such variations of the TLR2 gene, the low-prevalence variant Arg753Gln
(rs5743708) and the GTn microsatellite repeat polymorphism in intron 2. Of these two, the
Arg753Gln variant has been shown to cause impaired mucosal repair because of a deficient
ability to induce TFF3 synthesis [11] and has previously been associated with severe (extensive)
disease in ulcerative colitis [12]. The GTn repeat microsatellite polymorphism in intron 2 of
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the TLR2 gene was first described in 2004; the study found high variability in the numbers of
GT repeats starting at -100 bp from the ATG and ranging from 12 to 28 repeats [7]. The distri-
bution of allele lengths significantly differs among racial groups, and the number of GT repeats
seems to have functional implications. Short GT repeats have been shown to result in higher
TLR2 promotor activity [7, 13], and after stimulation with TLR2 agonists they result in higher
production of pro-inflammatory cytokines (TNF-alpha, IL-12 and IL-6) [13] and lower pro-
duction of anti-inflammatory cytokines (IL-10) [14]. Therefore, it has been speculated, that
short GT repeats are much more prone to inflammation than mid-sized repeats, which are
most abundant in every race [7]. Similar to CD-associated NOD2 variants [15], the microsatel-
lite polymorphism has recently been associated with susceptibility to develop spontaneous bac-
terial peritonitis in cirrhotic patients [16]. Furthermore, both polymorphisms have previously
been linked to mycobacterial disease [8, 17–20], which displays an important genetic overlap
with IBD, as mentioned above.
Methods
Ethics statement
The study was approved by the Ethics committee of the Medical Faculty of the Ludwig-Maxi-
milians-University Munich. Written, informed consent was obtained from all patients prior to
the study. Study protocols were based on the ethical principles for medical research involving
human subjects of the Helsinki Declaration.
Study population and IBD phenotype assessment
We recruited a large cohort comprising 2074 individuals of European origin. This popula-
tion included 1269 patients with IBD (CD, N = 843; UC, N = 426) and 805 healthy, unre-
lated controls. All participants included in the study were Caucasians. The patients were all
recruited at the University Hospital Munich, Germany. The diagnosis of CD or UC was
established by conventional clinical, radiological, endoscopic and histopathological criteria
[21]. Patients with indeterminate colitis were excluded from the study. The control popula-
tion comprised ethnically matched, healthy, unrelated blood donors. Demographic data are
given in Table 1.
Extensive clinical characterization was available for 760 patients with CD and 375 patients
with UC. Phenotypic data were collected by analysing patient charts and from a detailed ques-
tionnaire completed during an interview at the time of enrolment. The phenotypic classifica-
tion of CD and UC patients was based on the Montreal classification and included age at
diagnosis (A), location (L) and behaviour (B) of disease for CD and disease extension (E) for
UC [22]. The phenotypic data for patients with CD and UC are given in Tables 2 and 3,
respectively.
Genotyping
Genomic DNA was isolated from peripheral blood leucocytes with a commercially available
kit from Qiagen (Hilden, Germany) according to the manufacturer’s guidelines. Genotyping
of the polymorphism Arg753Gln (rs5743708) in the TLR2 gene was performed by restriction
fragment length polymorphism analysis, as previously described [23]. For genotyping of the
microsatellite polymorphism in intron 2 of the TLR2 gene we used polymerase chain reaction
(PCR) to amplify a region of 131–163 bp surrounding the GT repeat microsatellite, as previ-
ously described [6, 7]. The number of GT repeats was identified by length analysis of the PCR
products with an automatic sequencer. The total volume of the PCR mixture was 10 μl; the
TLR2 polymorphisms in inflammatory bowel disease
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mixture contained 50 ng of genomic DNA, 1×PCR buffer (Qiagen, Hilden, Germany), 0.2mM
of each dNTP (Sigma, Taufkirchen, Germany), 0.25 units of HotStar-Taq™DNA polymerase
(Qiagen) and 0.25μM each of the two primers 50FAM-GCATTGCTGAATGTATCAGGGA-30
(forward, containing the fluorescein marker 6-carboxyfluorescein [FAM]) and 50-CTTGAGAA
ATGTTTTCTAGGC-30 (reverse; TIB MOLBIOL, Berlin, Germany). The final concentration of
MgCl2 was 2mM. After an initial denaturation step at 95˚C for 15 min, samples were subjected
to 35 cycles of denaturation at 94˚C for 30 s, annealing at 55˚C for 30 s and elongation at 72˚C
for 30 s. This temperature regimen was followed by a final elongation step at 72˚C for 10 min.
The resulting fragments were run on an ABI 3700 sequencer. Samples for which genotypes
were previously confirmed by sequencing, i.e. (GT)13, (GT)19, (GT)23, and (GT)24, were used
as “gold standards” and were run in each gel separately.
Genotype information for the GTn repeat microsatellite polymorphisms in intron 2 of the
TLR2 gene was already available for 590 of the controls [16]. Genotypic data for the three CD-
associated NOD2 variants (rs2066844 = p.Arg702Trp, rs2066847 = p.Gly908Arg and
rs2066847 = p.Leu1007fsX1008) were available from previous studies [5].
Statistical analysis
Statistical analysis was performed with SPSS software version 14.0 (SPSS Inc, Chicago, IL) and
Python. The genotype frequencies for all investigated polymorphisms were tested for consis-
tency with the Hardy-Weinberg equilibrium.
For the case-control analysis, genotypes and allele frequencies were compared by employ-
ing χ over the weights of a logistic regression, with age, sex and the three first components of a
multidimensional scaling (MDS) as covariates. Bonferroni correction was applied for multiple
comparisons. P values< 0.05 were considered significant.
To test the microsatellite size effect we performed a logistic regression test for the different
thresholds. We repeated the test on random permutations of the phenotype to study the distri-
bution of P values.
Table 1. Demographic characteristics of the study population.
Crohn’s disease N = 843 Ulcerative colitis N = 426 Controls N = 805
Gender
Male (%) 48.9 50.2 55.5
Female (%) 51.1 49.8 44.5
Age (y)
Mean (SD) 34.7 (14.3) 37.4 (16.0) 45.6 (10.8)
Range 5–79 3–83 18–73
Body mass index
Mean (SD) 23.1 (4.2) 23.8 (4.0)
Range 13–41 15–41
Age at diagnosis (y)
Mean (SD) 25.0 (12.4) 27.9 (14.6)
Range 1–78 1–81
Disease duration (y)
Mean (SD) 8.5 (8.2) 7.5 (7.1)
Range <1–41 <1–38
Positive family history of IBD
% of participants 19.1 19.0 0.0
https://doi.org/10.1371/journal.pone.0175180.t001
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Table 2. Phenotypic characteristics of patients with Crohn’s disease for whom detailed phenotypic
data was available.
Phenotypic subgroups n (% of subgroup)
Age at diagnosis (Montreal A, n = 760)
A1, below 16 y 188 (24.7)
A2, between 17 and 40 y 484 (63.7)
A3, above 40 y 88 (11.6)
Location (Montreal L, n = 806)
L1, ileal 105 (13.0)
L2, colonic 185 (23.0)
L3, ileocolonic 505 (62.7)
L4, isolated upper disease 11 (1.3)
Behaviour1 (Montreal B, p = perianal disease modifier, n = 782)
B1, non-stricturing, non-penetrating 208 (26.6)
B1p 21 (2.6)
B2, stricturing 186 (23.8)
B2p 9 (1.2)
B3, penetrating 320 (40.9)
B3p 38 (4.9)
Any stenosis2 432 (55.2)
n/total analysed (%)
Extra-intestinal manifestations 225/469 (48.0)
Surgery because of Crohn’s disease3 393/774 (50.8)
Use of immunosuppressive agents4 356/437 (81.5)
Anti-TNF-alpha therapy 181/526 (34.4)
1Disease behaviour was defined according to the Montreal classification. A stricturing disease phenotype
was defined as presence of stenosis without penetrating disease. The diagnosis was made surgically,
endoscopically or radiologically (MRI enteroclysis).
2Presence of stenosis independent of penetrating disease
3Only surgery related to problems specific to Crohn’s disease (e.g. fistulectomy, colectomy, ileostomy) was
included
4Immunosupressive agents included azathioprine, 6-mercaptopurine, 6-thioguanin, MTX and anti-TNF-
alpha agents
https://doi.org/10.1371/journal.pone.0175180.t002
Table 3. Phenotypic characteristics of patients with ulcerative colitis for whom detailed phenotypic
data was available.
Phenotypic subgroups n (% of subgroup)
Location (Montreal E, n = 375)
E1, ulcerative proctitis 43 (11.5)
E2, left sided ulcerative colitis 118 (31.5)
E3, extensive ulcerative colitis 214 (57.1)
n/total analysed (%)
Extra-intestinal manifestations 60/166 (36.1)
Use of immunosuppressive agents 146/192 (76.0)
Anti-TNF-alpha therapy 56/227 (24.7)
https://doi.org/10.1371/journal.pone.0175180.t003
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The polymorphism information content (PIC) score for the GTn repeat microsatellite
marker in our study population was calculated by using the online PIC calculator (http://w3.
georgikon.hu/pic/english/kezi.aspx).
A classical linkage equilibrium test was performed with a χ test between the microsatellite
and rs5743708 polymorphism.
Results
Case-control association study of the GTn repeat microsatellite
polymorphism and the Arg753Gln (rs5743708) polymorphism in the
TLR2 gene
The distributions of genotypes for both TLR2 polymorphisms were consistent with Hardy-
Weinberg equilibrium.
The number of GT repeats in intron 2 of the TLR2 gene varied between 13 and 28 in both
the disease groups and the healthy controls (see Fig 1). The polymorphic information content
for the GTn repeat microsatellite polymorphism was 0.833, which can be considered highly
informative.
Given the trimodal distribution of GT repeats, we first categorized the alleles into three sub-
classes, as previously described for the analysis of microsatellite polymorphisms [24]. The
lower component with (GT)16 was designated as shorter “S allele”, the middle component
between (GT)17 and (GT)22 as the middle “M allele” and the upper component with (GT)23
as the long “L allele (Table 4). We than analysed the genotype distribution and divided the six
genotypes (S/S, S/M, S/L, M/M, M/L, L/L—see S1 Table) according to the presence or absence
of the S-allele in genotypes including the S-allele (S-allele carriers) or genotypes without the
S-allele (no S-allele carrier). This classification relied on observations from previous studies of
the microsatellite polymorphism suggesting the presence of short GT repeats to be dominant
over the presence of longer GT repeats [14]. Overall, the frequency of the S-allele and also the
genotype frequency for S-allele carriers were slightly higher in patients with CD and UC com-
pared to controls (Table 4). However, after correction for multiple testing, the multivariate
Fig 1. Allele frequencies for the GTn repeat microsatellite polymorphism in the study groups.
https://doi.org/10.1371/journal.pone.0175180.g001
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analysis including sex, age and the first three components of an MDS as covariates failed to
show a significant association of the microsatellite polymorphism with CD or UC.
As previously described in a report on spontaneous bacterial peritonitis in patients with
liver cirrhosis [16], we next focused on finding a possible cut-off for the number of GT repeats
that could best differentiate between patients and controls. First, we used a 10-fold cross vali-
dation for the different cut-offs to classify between controls and CD and UC patients but did
not obtain a significant result. Then, we compared the P values obtained by logistic regression
with the general distribution of P values and randomized the phenotype. The best results for
both CD and UC were obtained with the cut-off set at 18 GT repeats. We next also used the
cut-off 18, i.e. GTn, n18 or n>18, to test whether the allele and genotype frequencies for the
GTn repeat microsatellite polymorphism differed significantly between the study groups. The
allele frequency for short GT repeats (n18) was higher in CD patients and the combined IBD
group than in controls (9.1% vs. 6.8%). Correspondingly, the frequency of carriers of short GT
repeats (i.e. at least one short GTn, n18 allele) was higher in the CD, UC and combined IBD
groups (17.2%, 17.8% and 17.4%, respectively) than in controls (13.2%). However, also with
this cut-off the multivariate analysis found no significant associations of the microsatellite
polymorphism after correction for multiple testing (data not shown).
The allelic and genotype distributions of the SNP Arg753Gln (rs5743708) in the TLR2 gene
showed no significant differences between patients with CD or UC and controls. The allele
and genotype frequencies and the results of the univariate analysis are shown in Table 5.
Genotype-phenotype analysis: No significant association of the TLR2
polymorphisms with clinical subtypes in CD and UC
We further tested for a specific association of the TLR2 polymorphisms with clinical sub-
types in CD and UC. Such an association has already been described for the Arg753Gln
(rs5743708) polymorphism e.g. with extensive colitis in UC [12]. Furthermore, an associa-
tion of the polymorphisms with a specific clinical subgroup could possibly be responsible
for the moderate differences in the allele and genotype distributions observed for the
Table 4. Frequencies for the TLR2 intron 2 microsatellite GTn repeats in the study population.
Crohn’s disease (N = 843) Ulcerative colitis (N = 426) IBD (N = 1269) Controls (N = 805)
Frequency % P value, OR [95% CI] Frequency % P value, OR [95%
CI]
Frequency % P value, OR [95% CI] Frequency %
Allele frequencies2
S (GTn, n16) 8.6 p3 = 0.030, 1.34[1.02–
1.75]
8.3 n.s. 8.5 p3 = 0.026, 1.33[1.03–
1.70]
6.5
M (GTn,
16<n<22)
62.3 n.s. 62.7 n.s. 62.4 64.3
L (GTn, n16) 29.1 n.s 29.0 n.s. 29.1 29.1
Genotype frequencies
S-allele carriers 16.0 n.s. 16.7 n.s. 16.4 p3 = 0.031, 1.33[1.03–
1.73]
12.8
No S-allle 84.0 83.3 83.6 87.2
1The category IBD (inflammatory bowel disease) represents the combined Crohn’s disease (CD) and ulcerative colitis (UC) cohort.
2S (GT)16, (GT)17 <M < (GT)22 and L (GT)23. Allelic and genotypic test P values and OR (odds ratios) with 95% CI (confidence intervals) are shown for
the CD and UC groups compared to controls.
3Significant tests (p<0.05) in the univariate analysis, loss of significance after correction for multiple testing.
https://doi.org/10.1371/journal.pone.0175180.t004
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microsatellite polymorphism in the case-control study. Patients were categorised according
to their genotype into short allele carriers (at least one S allele) or not short allele carriers
(both GTn alleles M or L). Similarly, for the Arg753Gln polymorphism carriers of at least
one mutated allele (homozygous or heterozygous Arg753Gln carriers) were compared with
Arg753Gln wildtype individuals. The results of the subgroup analyses are shown in Tables 6
and 7 for CD and UC, respectively.
As shown in Table 6, the frequency of short GTn allele carriers in the group of CD patients
with age at diagnosis above 40 years (Montreal A3, 6.8%) was lower than in the groups with
age at diagnosis below 16 years (Montreal A1; 16.5%) and between 17 and 40 years (Montreal
Table 5. Frequencies for the TLR2 Arg753Gln (G/A) polymorphism in the study population.
Crohn’s disease (N = 837) Ulcerative colitis (N = 401) IBD1 (N = 1238) Controls (N = 784)
Frequency % P value, OR[95% CI] Frequency % P value, OR[95% CI] Frequency % P value, OR[95% CI] Frequency %
Allele frequencies
A 3.3 n.s. 3.9 n.s. 3.5 n.s. 3.2
Genotype frequencies
AA 0.3 n.s. 0.0 n.s. 0.2 n.s. 0.1
AG 6.0 7.7 6.6 6.1
GG 93.7 92.3 93.2 93.8
1The category IBD (inflammatory bowel disease) represents the combined Crohn’s disease (CD) and ulcerative colitis (UC) cohort. Allelic and genotypic test
P values and OR (odds ratios) with 95% CI (confidence intervals) have been calculated for the CD, UC and IBD groups compared to controls. No significant
associations (p<0.05) resulted in the univariate analysis.
https://doi.org/10.1371/journal.pone.0175180.t005
Table 6. Frequencies of carriers of at least one short (S-allele) for the GTn microsatellite polymorphisms in the specific phenotypic subgroups for
Crohn’s disease.
TLR2 microsatellite GTn repeat S- allele carriers / Total (%) p, OR [95% CI]1
Age at diagnosis (Montreal A, n = 760)
A1, below 16 y 31 / 188 (16.5) n.s.
A2, between 17 and 40 y 81 / 484 (16.7) n.s.
A3, above 40 y 6 / 88 (6.8) p = 0.018, 0.37 [0.14–0.90]
Location (Montreal L, n = 806)
L1, ileal 17 / 105 (16.2) n.s.
L2, colonic 33/ 185 (17.8) n.s.
L3, ileocolonic 80 / 505 (15.8) n.s.
L4, isolated upper disease 0 / 11 (0.0) n.s.
Behaviour (Montreal B, n = 782)
B1, non-stricturing, non-penetrating 34 / 229 (14.9) n.s.
B2, stricturing 33 / 195 (16.9) n.s.
B3, penetrating 59/ 358 (16.5) n.s.
Any stenosis 72 / 432 (16.7) n.s.
Extra-intestinal manifestations 35 / 225 (15.6) n.s.
Surgery because of CD 62/ 393 (15.8) n.s.
Use of immunosuppressive agents 62/ 356 (17.4) n.s.
Anti-TNF-alpha therapy 34 / 181 (18.8) n.s.
1Allelic and genotypic test P values and OR (odds ratios) with 95% CI (confidence intervals) are shown for short S-allele carriers compared to those who
were not short allele carriers (both GTn alleles M or L) in the specific clinical subgroups. Significant tests (p<0.05) in the univariate analysis are shown as
values, not significant tests as shown n.s.
https://doi.org/10.1371/journal.pone.0175180.t006
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A2; 16.7%) and lower than in the controls (12.8%). However, only 88 CD patients were
included in the subgroup Montreal A3, and the difference was not significant after correction
for multiple testing. Similarly, the frequency of carriers of at least one S -allele was higher in
CD patients with isolated colonic disease (17.8%) and in CD patients needing immunosup-
pressive therapy (16.7%), especially anti-TNF-alpha agents (18.8%), than in CD patients with
no need for immunosuppressive therapy, but this differences were also not significant after
correction for multiple testing.
In patients with ulcerative colitis the frequency of S-allele carriers was also slightly higher in
patients needing immunosuppressive therapy, in particular anti-TNF-alpha therapy (21.4%),
and in those with extraintestinal disease manifestations (23%), but again these differences were
not significant after correction for multiple testing.
Regarding the polymorphism Arg753Gln, we did not find a significantly higher frequency
of Arg753Gln carriers in patients with extensive ulcerative colitis (see Table 7), although this
has been previously described [12]. Analyses revealed no other significant association with
clinical subgroups for CD or UC.
Gene-gene interactions
On a functional level, the TLR2-mediated response to bacterial peptidoglycan is modulated by
NOD2 and this modulation is disturbed in the presence of NOD2 mutations associated with
CD [25, 26, 27]. We tested here for evidence of genetic interactions between the polymor-
phisms in TLR2 and disease-associated NOD2 variants with possible implications for suscepti-
bility to CD. Such interactions have been described for spontaneous bacterial peritonitis in
cirrhotic patients, with a significant increase in disease risk in the presence of both disease-
associated NOD2 variants and long GTn repeats for the TLR2 microsatellite polymorphism
Table 7. Frequencies of carriers of at least one short (S-allele) for the intron 2 microsatellite repeat polymorphism or at least one Arg753Gln allele
in the TLR2 gene in the specific phenotypic subgroups for ulcerative colitis.
TLR2 microsatellite GTn repeats S-allele carriers / Total (%) p, OR [95% CI]1
Location (Montreal E, n = 375)
E1 (Ulcerative proctitis) 6 / 43 (14.0) n.s.
E2 (Left sided ulcerative colitis) 21 / 118 (17.8) n.s.
E3 (extensive ulcerative colitis) 37 / 214 (17.3) n.s.
Extra-intestinal manifestations 14 / 60 (23.0) p = 0.048, 2.38 [0.95–6.04]
Use of immunosuppressive agents 30 / 146 (20.5) n.s.
Anti-TNF-alpha therapy 12 / 56 (21.4) n.s.
TLR2 Arg753Gln Arg753Gln allele carriers / Total (%) P, OR [95% CI]2
Location (Montreal E, n = 375)
E1 (Ulcerative proctitis) 3 / 43 (7.0) n.s.
E2 (Left-sided ulcerative colitis) 6 / 108 (5.6) n.s.
E3 (Extensive ulcerative colitis) 16 / 203 (7.9) n.s.
Extra-intestinal manifestations 5 / 54 (9.3) n.s.
Use of immunosuppressive agents 7 / 131 (5.3) n.s.
Anti-TNF-alpha therapy 4 / 49 (8.2) n.s.
1Allelic and genotypic test P values and OR (odds ratios) with 95% CI (confidence intervals) are shown for S-allele carriers compared to those who were not
short allele carriers (both GTn alleles M or L) in the specific clinical subgroups.
2Allelic and genotypic test P values and OR (odds ratios) with 95% CI (confidence intervals) are shown for Arg753Gln allele carriers compared to Arg753Gln
wildtype individuals in the specific clinical subgroups. Significant tests (p<0.05) in the univariate analysis are shown as values, not significant tests as shown
n.s.
https://doi.org/10.1371/journal.pone.0175180.t007
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[16]. The frequency of short (S-allele) carriers for the GTn repeat microsatellite polymorphism
in TLR2 was slightly higher among CD patients carrying at least one CD-associated NOD2 var-
iant compared to wildtype NOD2 CD-patients (17.2% vs. 15.1%), but this difference was not
significant. Similarly, the polymorphism Arg753Gln showed no significant interactions with
NOD2 variants in CD.
Our cohort has previously been genotyped for further IBD susceptibility variants. We next
tested for possible interactions between the two TLR2 polymorphisms and variants in IL23R,
ATG16L1, IBD5, TLR4 and TLR9 [5, 28]. However, this test revealed no significant epistatic
interactions for the polymorphisms in TLR2 and known disease-associated variants in these
genes.
We found a highly significant correlation between the number of GTn repeats in intron 2 of
the TLR2 gene and the polymorphism Arg753Gln (rs5743708) (r = 0.0099038, P = 2.76 × 10−10)
(see S1 Fig). This finding is in accordance with the previously reported strong linkage disequi-
librium between the two polymorphisms [29]. A regional LD plot for the SNP rs5743708
(Arg753Gln) in TLR2 on the Chr. 4q31.3 identified no other variant in strong LD (r20.8) with
this SNP (see S2 Fig). For the other three genes located in the same region of Chromosome 4:
KIAA0922 = TMEM131L (transmembrane protein 131-like), RNF175 (ring finger protein 175)
and SFRP2 (secreted frizzled-related protein 2), no literature data linking them to inflammatory
bowel disease or mycobacterial disease has been found.
Discussion
In the present investigation we analysed the role of two functionally relevant polymorphisms
in TLR2, the coding variant Arg753Gln (rs5743708) and the GTn repeat microsatellite poly-
morphism in intron 2, in the susceptibility for IBD in a large European cohort. Both TLR2
polymorphisms seem to affect immune responses (e.g. cytokine release) after stimulation with
bacterial products [6, 7, 13, 14] and have previously been linked to susceptibility to mycobacte-
rial disease [8, 17–20]. Given the considerable overlap between susceptibility for IBD and
mycobacterial infection revealed by GWAS [1] and the substantial amount of still “hidden”
heritability in IBD, the TLR2 polymorphisms represent interesting candidates for CD and UC
susceptibility.
Our study is the first to assess the distribution of the TLR2 intron 2 GTn repeat microsatel-
lite polymorphism in IBD. Previous investigations reported an association of this polymor-
phism with various mycobacterial diseases such as nontuberculous mycobacterial lung disease
[18], tuberculosis [19, 20] and also leprosy [13]. Overall, the number of GTn repeats in our
population varied between 13 and 28, with peak frequencies at 13, 19–21 and 24 repeats, which
is in accordance with the distribution reported in the original description in Caucasians [7].
We observed a slightly higher frequency for short (S, with (GT)16) GT repeats in patients
with CD and UC compared to controls. The genotype frequency for carriers of at least one S-
allele was also slightly higher in IBD patients compared to controls. However, these differences
were all not significant in the multivariate analysis. The further stratification of alleles with the
cut-off of 18 GT repeats, which was found to best differentiate between patients and controls,
did also not revealed any significant differences in the distribution in CD and UC compared to
controls.
Because clinical phenotypes of IBD are partially genetically determined, we also conducted
an extensive genotype-phenotype analysis to identify possible associations of the GTn repeat
microsatellite polymorphism with subgroups in CD or UC. This analysis found a slightly
higher frequency of carriers of short GTn repeats among the CD and UC patients with a need
for immunosuppressive treatment, but this difference was also not significant in the
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multivariate analysis. Thus, our data do not provide evidence for a specific association of the
microsatellite polymorphism with a phenotypic subgroup in CD or UC.
Besides leprosy, for which a clear link to CD susceptibility genes like NOD2 [30] and IL23R
[31] has been established, the microsatellite polymorphism in TLR2 has been associated with
further infectious conditions linked to CD-associated NOD2 variants, like the susceptibility to
develop spontaneous bacterial peritonitis in liver cirrhosis [15, 16]. Interestingly, in this setting
the coexistence of longer GTn repeats for the microsatellite polymorphism and NOD2 muta-
tions was associated to an additive risk to develop spontaneous bacterial peritonitis [16]. Our
study instead, failed to show any interaction of the microsatellite polymorphism with NOD2
variants in CD. Further epistasis testing did not reveal any interactions of the microsatellite
polymorphism with other susceptibility IBD variants in IL23R, ATG16L1, IBD5, TLR4 and
TLR9.
Studies on the influence of the length of GTn repeats on TLR2 function have shown higher
promotor activity [7] and TLR2mRNA expression [13] as well as higher production of proin-
flammatory cytokines and lower production of anti-inflammatory cytokines [13, 14] for short
GTn repeats. Therefore, it has been speculated, that the shorter allele is much more prone to
inflammation than mid-sized repeats and this would possibly explain why mid-sized alleles are
most abundant in every race [7]. In comparison, S-alleles are relatively rare. As our study had
sufficient power to detect disease associations for uncommon genetic variations with higher
effect size, the negative results of the study exclude the GTn microsatellite polymorphism as a
disease associated variant with a significant effect size.
Regarding the low-prevalence variant Arg753Gln (rs5743708) in TLR2, a previous case-
control association study comprising 285 European IBD patients (of which 106 had UC)
described an association of this variant with pancolitis, with a relative risk of 3.3 in heterozy-
gous patients [12]. In our well-powered investigation we found no significant association of
this polymorphism with CD or UC but a comparable frequency of the polymorphism in all
study groups. Recently Cheng et al. [32] performed an extensive meta-analysis on the associa-
tion of TLR2 and TLR4 polymorphisms with IBD. The studies included in the meta-analysis
assessed the frequency of the TLR2 Arg753Gln polymorphism in a total of 718 patients with
UC and 1454 patients with CD. The meta-analysis found no significant association of the poly-
morphism Arg753Gln with CD or UC in any of the genetic models [32] but the meta-analysis
did not included a subgroup analysis of specific disease phenotypes in UC or CD. However,
our subgroup analysis failed to show an association of the polymorphism with extensive dis-
ease in ulcerative colitis.
In conclusion our case-control association study revealed no significant role of the func-
tional relevant polymorphisms in TLR2, the GTn microsatellite repeat polymorphism in intron
2 and the Arg753Gln in the susceptibility to Crohn’s disease or ulcerative colitis.
Supporting information
S1 Fig. Correlation between the Arg753Gln (rs5743708) genotype and the number of GTn
repeats for the microsatellite polymorphism in TLR2. TLR2 753 mutated = carriers of at
least one Arg753Gln allele.
(TIF)
S2 Fig. Regional LD plot for rs5743708 in TLR2 on Chromosome 4q31.3. The pairwise LD
(r2) between this SNP and surrounding variants and the estimated recombination rate are
plotted as a function of genomic position. The plot was constructed by SNAP (SNMP Annota-
tion and Proxy Search, http://archive.broadinstitute.org/mpg/snap/ldplot.php) using the CEU
population panel in the 1000 Genome Project (1000GP) Pilot 1 data and a 250 kilobases (kb)
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distance limit on each side. Three other genes are located in this region on Chromosome 4:
KIAA0922 = TMEM131L (transmembrane protein 131-like), RNF175 (ring finger protein 175)
and SFRP2 (secreted frizzled-related protein 2).
(TIF)
S1 Table. Frequencies for TLR2 intron 2 microsatellite GTn repeats genotypes in the study
population.
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